22503-17-9

Basic information

• Product Name: 3,5-DIAMINO-TERT-BUTYLBENZENE
• Synonyms: 3,5-DIAMINO-TERT-BUTYLBENZENE;5-tert-Butyl-1,3-benzenediamine;5-tert-Butyl-1,3-phenylenediamine;5-tert-butylbenzene-1,3-diamine
• CAS NO: 22503-17-9
• Molecular Formula: C₁₀H₁₆N₂
• Molecular Weight: 164.25
• Mol File: 22503-17-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 308.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.022±0.06 g/cm3(Predicted)
• PKA: 4.98±0.10(Predicted)
• CAS DataBase Reference: 3,5-DIAMINO-TERT-BUTYLBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIAMINO-TERT-BUTYLBENZENE(22503-17-9)
• EPA Substance Registry System: 3,5-DIAMINO-TERT-BUTYLBENZENE(22503-17-9)

Safety Data

• Hazardous Substances Data: 22503-17-9(Hazardous Substances Data)

Upstream product

• 769-92-6 4-tert-Butylaniline 
• 10546-67-5 2,6-dibromo-4-(tert-butyl)aniline 
• 129316-09-2 1,3-dibromo-5-t-butylbenzene 
• 156264-80-1 1,3-dibromo-5-tert-butylbenzene 
• 2213-81-2 2-chloro-5-(1,1-dimethylethyl)-1,3-dinitrobenzene 
• 22503-19-1 4,6-Dinitro-2,5-di-t-butyl-acetanilid 
• 22161-99-5 4-Nitro-2,5-di-t-butylacetanilid 
• 10472-73-8 2,5-di-tert-butyl-1,3-dinitro-benzene 
• 22503-21-5 2-Amino-3,5-dinitro-1,4-di-t-butylbenzol 
• 3463-35-2 2,5-di-tert-butylnitrobenzene 
• 22503-14-6 2.5-di-tert-butyl-m-phenylenediamine 
• 22385-63-3 1-tert-butyl-3,5-dinitro-benzene 

Downstream Products

• 1041054-03-8 N-(3-amino-5-(tert-butyl)phenyl)methanesulfonamide 

Relevant articles and documents

Electronic Ligand Modifications on Cobalt Complexes and Their Application toward the Semi-Hydrogenation of Alkynes and Para-Hydrogenation of Alkenes

The effect of the electronic modification of a bis(carbene) pincer ligand, (MesCCCR), on cobalt catalysis has been investigated. The pincer ligand was modified in the para position of the aryl backbone with a tert-butyl and trifluoromethyl moiety to yield the electronic variants that were applied toward the synthesis and characterization of several cobalt complexes, (MesCCCR)Co. The application of the (MesCCCR)CoI(N2)PPh3 complexes toward the semihydrogenation of alkynes revealed that while the tert-butyl group does not impact reactivity, the loss of electron density at the metal center, by the installation of the CF3 group, does affect product ratios. Further inspection of the proposed mechanism suggested that the installation of the trifluoromethyl group slows down olefin hydrogenation. This finding was further supported in the application of the (MesCCCR)CoI-py (py = pyridine) complexes toward the parahydrogenation of ethyl acrylate, which demonstrated that the electron-withdrawing ligand variant produced less polarization.

A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790Mmutant with improved pharmacokinetic properties

Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790Minhibitors with improved pharmacokinetic properties. One of the most promising compound 9s potently suppressed EGFRL858R/T790Mkinase and inhibited the proliferation of H1975?cells with IC50values of 2.0?nM and 40?nM, respectively. The compound dose-dependently induced reduction of the phosphorylation of EGFR and downstream activation of ERK in NCI[sbnd]H1975?cells. It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%. Compound 9s may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.

UREA DERIVATIVES USEFUL AS KINASE INHIBITORS

There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.